New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
09:13 EDTAPU, SNSS, LULU, NBL, CLF, RH, CNX, GERNOn The Fly: Pre-market Movers
HIGHER: Geron (GERN), up 28.5% after FDA removes partial clinical hold on imetelstat trial... Restoration Hardware (RH), up 17.7% after reporting better than expected Q1 earnings and raising its FY14 outlook... Sunesis (SNSS), up 5.6% after stock was initiated with a Buy rating and $14 price target at UBS... CONSOL Energy (CNX), up 0.6%, and Noble Energy (NBL), up 0.8%, after the company said they intend to form a master limited partnership to provide midstream gathering services for production from their jointly owned acreage in the Marcellus Shale. LOWER: lululemon (LULU), down 17% after reporting on quarter, lowering FY14 normalized EPS view, shares downgraded at William Blair and at Stifel... AmeriGas (APU), down 5% after its 8.5M share spot secondary offering priced at $45.80 per unit... Cliffs Natural (CLF), down 2.7% after Casablanca Capital sends letter to shareholders in support of its 6 board nominees, Morgan Stanley said in a note to investors that Cliffs' dividend at risk.
News For RH;LULU;GERN;CLF;SNSS;CNX;NBL;APU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 13, 2014
16:28 EDTGERNGeron announces global strategic collaboration with Janssen Biotech
Geron (GERN) announced that the company has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, a Johnson & Johnson (JNJ) company, to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Imetelstat is a modified oligonucleotide that is currently in early phase clinical development for myelofibrosis, or MF, and may have activity in other hematologic myeloid malignancies such as myelodysplastic syndrome, or MDS, and acute myelogenous leukemia, or AML. Under the terms of the agreement, Geron will receive an initial payment of $35M due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900M for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities. All sales will be booked by Janssen.
13:32 EDTGERNLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTGERNLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTGERNLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
06:04 EDTLULUStocks with implied volatility above IV index mean; GME LULU
Subscribe for More Information
November 12, 2014
18:04 EDTAPUAmeriGas sees FY15 net income $308M-$338M, consensus $2.83
Subscribe for More Information
18:01 EDTAPUAmeriGas reports Q4 EPS (58c), consensus (55c)
Subscribe for More Information
15:29 EDTAPUNotable companies reporting after market close
Subscribe for More Information
13:31 EDTLULULululemon Athletica volatility elevated as shares trend higher
Subscribe for More Information
07:46 EDTCNXCowen to hold a conference
Subscribe for More Information
07:31 EDTNBLBofA/Merrill to hold a conference
Subscribe for More Information
November 11, 2014
16:14 EDTGERNLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.
09:59 EDTCLFCliffs Natural calls active
Subscribe for More Information
09:50 EDTCLFRumor: Cliffs Natural moves up on renewed takeover chatter
Subscribe for More Information
November 10, 2014
09:46 EDTLULUBB&T remains positive on lululemon following channel checks
BB&T said it remains positive on lululemon following recent channel checks. The firm continues to expect lululemon's results to improve as the company improved product assortment and laps 2013 PR stumbles. BB&T views the hire of Duke Stump as EVP of Community and Brand as a a positive and views the controversy over the donation to the Dalai Lama Center as overblown. Shares are Buy rated with a $50 price target.
09:20 EDTSNSSOn The Fly: Pre-market Movers
Subscribe for More Information
09:20 EDTCLFNucor unlikely to partner on Cliffs Natural asset, says Bernstein
Subscribe for More Information
07:22 EDTLULUU.S. Retail Softlines sector downgraded to Negative at Barclays
Subscribe for More Information
07:13 EDTSNSSSunesis reports Q3 EPS (25c), consensus (17c)
Subscribe for More Information
05:48 EDTLULUU.S. Retail Softlines industry cut to Negative at Barclays
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use